Roundtable Discussion; The Future of Mineral Sands. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksMXC.L Share News (MXC)

  • There is currently no data for MXC

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

TRADING UPDATES: Marlowe executes strategy with whirl of acquisitions

Tue, 02nd Mar 2021 17:12

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Tuesday and not separately reported by Alliance News:

----------

Marlowe PLC - London-based safety & compliance services - Acquires HR software business YouManage for GBP1.3 million. Acquires law compliance specialists ESP, ESP Law, and ESP Safeguard for GBP3.2 million. Acquires HR compliance specialist HR Services Partnership for GBP700,000. "These acquisitions are consistent with the three-year strategy recently announced at Marlowe's capital markets day to deepen and broaden our presence in core markets from selective acquisitions," says Marlowe Chief Executive Alex Dacre.

----------

Pantheon Resources PLC - oil & gas exploration company focused on Alaska - Announces the drilling of a new sidetrack into Kuparuk formation at Talitha A well in Alaska after encountering a problem with swelling. "As far as problems go, it's a good problem to have because it was driven by the preliminary data being better than expected at this location and warrants the opportunity to be tested rigorously," says Chief Executive Jay Cheatham.

----------

Nuformix PLC - pharmaceutical development firm based in London - Reports positive results for NXP002, an inhaled tranilast used to treat idiopathic pulmonary fibrosis. Says the study, performed by Newcastle Fibrosis Research Group, examined both the anti-fibrotic and anti-inflammatory potential of NXP002 in combination with the current standard of care, or SOC, therapies. Says the preliminary data from this study shows that the combination of NXP002 with SOC provided strong evidence of additional effects compared to either SOC alone on both fibrotic and inflammatory markers.

----------

Altus Strategies PLC - Africa-focused mining royalty company - Finds broad and high-grade intersections at Tabakorole gold project in Mali. "These are very encouraging drilling results from the Tabakorole gold project in southern Mali. Tabakorole hosts a significant gold resource, which is open along strike in both directions as well as at depth," says Chief Executive Steven Poulton. Says the holes are expected to improve the modelled mineralised grades and widths in a portion of the orebody.

----------

Mycelx Technologies Corp - clean water firm based in Minnesota - Says it has made a strong start to the year with two project extensions signed with customers in Saudi Arabia. "These projects confirm that Mycelx's superior solutions continue to support its customers' efforts to optimise production, increase cost savings and improve energy efficiency," says Mycelx. Expects to commence delivery of the equipment for its third sale to Nigeria in the first quarter of 2020.

----------

Alba Mineral Resources PLC - mineral exploration and development company with assets in Greenland and the UK - Says the physical attributes of the veins intersected at Clogau in Wales reflect the characteristics of the veins that were successfully mined in the past. Says this means that it "could well be a significant contributor to future production", adding that it is necessary to await the results of the drill core assays before reaching any preliminary conclusions.

----------

MGC Pharmaceuticals Ltd - Europe-based biopharmaceutical company - Says Swiss PharmaCan AG increases initial purchase order volume by 85% for first Artemic Rescue production batch, bringing the initial purchase order value to in excess of USD425,000 wholesale revenue to MGC. The initial agreement included a minimum wholesale order quantity of 40,000 units of per quarter. ArtemiC is a clinically tested food supplement containing four natural based ingredients consisting of artemisinin, curcumin, boswellia serrata, and vitamin C.

----------

PetroNeft Resources PLC - Russia-focused oil & gas exploration and production company - Says the hydraulic fracture stimulation program of wells on both the Sibkrayevskoye and the Lineynoye fields successfully completed. Initial results from the wells are "very encouraging". Says the aim of fracking the well was not only to increase production, but also to provide crucial information which can lead to an improved understanding of the optimum forward development plan for the field.

----------

Safestay PLC - hostels operator based in London - Announces sale of 96-bed hostel Barcelona Sea to Beds & Foods Barcelona for EUR900,000. The annual earnings before interest, tax, depreciation and amortisation of the hostel pre Covid-19 was EUR70,000. Says the proceeds will got to paying off the debt for the purchase of another hostel in Barcelona in 2018.

----------

By Greg Roxburgh; gregroxburgh@alliancenews.com

Copyright 2021 Alliance News Limited. All Rights Reserved.

More News
1 Sep 2022 17:52

TRADING UPDATES: Strong interim results from Johnson Service, Eurocell

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Thursday and not separately reported by Alliance News:

Read more
25 Aug 2022 16:26

TRADING UPDATES: Malvern revenue jumps; Rockwood eyes Main Market

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Thursday and not separately reported by Alliance News:

Read more
18 Aug 2022 11:57

IN BRIEF: Graft Polymer wins first commercial order for GraftBio

Graft Polymer (UK) PLC - London-based company focused on the development and production of polymer modification, biological supplements, and nano-drug delivery systems - Wins first commercial purchase order for its GraftBio division. Order for 50,000 units of its anti-inflammatory supplement, ArtemiC Rescue from MGC Pharmaceuticals PLC. Order worth around USD1 million. Production to start immediately. Delivery expected over the next three months. Chief Executive Victor Volduev says he expects follow-on orders in the coming quarters.

Read more
17 Aug 2022 11:12

MGC shares rise on USD1 million order for ArtemiC

(Alliance News) - MGC Pharmaceuticals Ltd shares were lifted on Wednesday after it announced a USD1 million order for its neutraceutical, ArtemiC.

Read more
15 Aug 2022 17:31

IN BRIEF: MGC Pharma's CannEpil found safe for driving in study

MGC Pharmaceuticals Ltd - Perth, Australia-based medicinal cannabis company - Says clinical study results for its epilepsy treatment, CannEpil, are complete. The study found CannEpil to be safe for post-treatment driving activities. It used a driving simulator to test whether the drug caused somnolence, ie drowsiness, or impairs cognition. It was sponsored by Cannvalate Australia, and conducted by the Centre of Human Psychopharmacology at Swinburne University of Technology, under the Medical Cannabis Research Collaboration.

Read more
5 Aug 2022 14:58

TRADING UPDATES: 4D Pharma warns of wind-up; Star Phoenix files claim

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Thursday and Wednesday and not separately reported by Alliance News:

Read more
29 Jul 2022 19:36

TRADING UPDATES: Walker Crips assets grow; Minoan interim loss narrows

(Alliance News) - The following is a round-up of earnings by London-listed companies, issued on Friday and not separately reported by Alliance News:

Read more
28 Jul 2022 20:08

TRADING UPDATES: Scottish American outperforms; Amte picks Dundee

(Alliance News) - The following is a round-up of earnings by London-listed companies, issued on Thursday and not separately reported by Alliance News:

Read more
25 Jul 2022 21:53

IN BRIEF: MGC Pharmaceuticals quarterly sales "strong"

MGC Pharmaceuticals Ltd - Perth, Australia-based medicinal cannabis company - Says "strong" quarterly sales continue, notes AUD1.6 million, about GBP923,000, in cash receipts during three month period to June 30. In 12-month period, records AUD6.1 million in cash receipts.

Read more
14 Jul 2022 21:44

TRADING UPDATES: Shield closer to Canada approval; Angle plans raise

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Thursday and not separately reported by Alliance News:

Read more
8 Jul 2022 14:19

IN BRIEF: MGC Pharmaceuticals wins approval for Covid study, shares up

MGC Pharmaceuticals Ltd - Perth, Australia-based medicinal cannabis company - Receives approval from South African Health Products Regulatory Authority for a Phase 2b dose finding study of its nanoparticle formulation CimetrA on patients diagnosed with Covid-19.

Read more
6 Jul 2022 20:08

IN BRIEF: MGC Pharmaceuticals launches medical data app ZAM

MGC Pharmaceuticals Ltd - Perth, Australia-based medicinal cannabis company - Says it is set to launch a real-time data collection application, ZAM, for use across the pharmaceutical and health care sectors, in collaboration with software development company, Caba Tech. The app will be available during the third quarter and will enable patients to log their medical history and monitor their medication use. ZAM, through the collection the patient data, will also provide users with a more complete understanding of their health and treatments, it says.

Read more
27 Jun 2022 20:27

IN BRIEF: MGC's CimetrA shows promise beyond Covid applications

MGC Pharmaceuticals Ltd - Perth, Australia-based medicinal cannabis company - Says preliminary results from pre-clinical in vitro study of CimetrA show it could have "wide-ranging application" as anti-inflammatory treatment. This is through the treatment's modulation of the production of pro-inflammatory cytokines. The study was undertaken by Israeli contract research organisation, Science in Action. Results support previous findings from a 2020 study into Covid-19, which showed CimetrA modulates the body's production of cytokines, which can lead to a cytokine storm, a type of severe immune reaction. New results support the potential of CimetrA to have a wider-ranging application as anti-inflammatory treatment, beyond the treatment of Covid-19 symptoms.

Read more
24 Jun 2022 10:13

IN BRIEF: MGC Pharma moves ahead with Covid-19 treatment in US

MGC Pharmaceuticals Ltd - Perth, Australia-based medicinal cannabis company - Progresses plans to begin US clinical trial for its Covid-19 treatment CimetrA, as MGC and AMC Holdings Inc executives meet with department heads from the University of South Florida. Parties also discuss regulatory approvals for phytocannabinoid medicines CogniCann and CannEpil in the US for early patient access schemes. Says US market access and distribution agreement has been signed with minimum orders of USD24 million over three years, including CimetrA.

Read more
16 Jun 2022 13:43

IN BRIEF: MGC Pharmaceuticals completes research study on brain cancer

MGC Pharmaceuticals Ltd - Perth, Australia-based medicinal cannabis company - Completes an in-vitro preclinical research study with the National Institute of Biology into the use of cannabinoids to treat brain cancer. The company says the study, undertaken on 30 biopsy samples from 18 patients over a period of three years, sought to determine the optimal formulation for the treatment of Glioblastoma, a form of brain cancer. The study showed that MGC Pharma's proprietary formulations were cytotoxic to Glioblastoma tumour and stem cells, reducing the cells' viability and inducing caspase-dependent cell apoptosis, or cell death.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.